Vertex Pharmaceuticals Inc. closed $108.22 short of its 52-week high ($519.88), which the company achieved on November 8th.

The health data company, based in Bellevue, Washington, plans to collect leftover specimens from consenting patients who get routine health care at participating facilities, Stat reported. Also in the ...

It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report)‘s stock had its “outperform” rating reaffirmed by stock analysts at ...

Vertex Pharmaceuticals VRTX has outperformed the market over the past 10 years by 1.52% on an annualized basis producing an ...

The company's collaboration partner, Vertex Pharmaceuticals(NASDAQ: VRTX), made progress activating authorized treatment centers capable of administrating Casgevy, but CRISPR still hasn't reported any ...

People visit the booth of Johnson & Johnson at the China International Import Expo (CIIE) in Shanghai, China November 7, 2024. REUTERS/Andrew Silver/File Photo Johnson & Johnson said on Monday it ...

Growth stocks are getting hammered by soaring bond yields. First off, long-dated bond yields have taken a wrecking ball to ...

The company anticipates launching three CRISPR products by 2030, including therapies for hereditary angioedema and ...